FRANKFURT — Deutsche Bank Research has maintained its 'Buy' rating on Novartis AG with a price target of 140 Swiss francs, according to an analysis published Wednesday. The assessment, authored by analyst Emmanuel Papadakis, follows the latest weekly prescription data for Novartis' drug portfolio.
The upgrade comes amid a broader market environment characterized by elevated valuations and increased risk aversion among investors. Deutsche Bank Research's note does not specify the date of the underlying study but was first distributed at 07:58 CET on Aug. 19, 2026.
Novartis' shares trade under the ISIN CH0012005267. The company remains a focal point for European healthcare equity coverage as macroeconomic headwinds and sector-specific dynamics continue to shape investor sentiment.
